Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

46.81USD
24 May 2019
Change (% chg)

$-0.49 (-1.04%)
Prev Close
$47.30
Open
$47.40
Day's High
$47.54
Day's Low
$46.78
Volume
1,975,315
Avg. Vol
4,762,316
52-wk High
$63.69
52-wk Low
$44.30

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $76,568.27
Shares Outstanding(Mil.): 1,635.72
Dividend: 0.41
Yield (%): 3.50

Financials

  BMY.N Industry Sector
P/E (TTM): 14.82 31.17 35.48
EPS (TTM): 3.16 -- --
ROI: 21.08 12.05 11.75
ROE: 36.90 13.36 16.52

Bristol-Myers' Opdivo fails late-stage brain cancer trial

Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.

May 09 2019

Bristol-Myers' Opdivo fails late-stage brain cancer trial

May 9 Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.

May 09 2019

UPDATE 1-Puerto Rico board files flurry of lawsuits ahead of claim deadline

SAN JUAN, April 30 Puerto Rico's federally created financial oversight board on Tuesday began filing the first round of scores of lawsuits seeking to recover money the bankrupt U.S. commonwealth paid to bondholders, businesses and others.

Apr 30 2019

Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Apr 30 2019

UPDATE 3-Vaccine and blood thinner help drive Pfizer to quarterly earnings beat

April 30 Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates and slightly raised its 2019 earnings forecast, as the company reined in costs and recorded higher sales of blood thinner Eliquis and Prevnar pneumonia vaccine.

Apr 30 2019

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

NEW YORK U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Apr 25 2019

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

NEW YORK, April 25 U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Apr 25 2019

Latest battle in war on class actions: 7th, D.C. Circuits will scrutinize nationwide cases

Sometimes threats to curtail class actions arise with little warning.

Apr 24 2019

Deals of the day-Mergers and acquisitions

April 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

Apr 12 2019

Bristol-Myers says shareholders vote to approve Celgene takeover

NEW YORK Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Apr 12 2019

Earnings vs. Estimates